Dyax Goes Live with Ross Systems to Support Enterprise Operations; iRenaissance Supports Emerging Life Sciences Companies for Improved Operational Effectiveness.

Business Editors/High-Tech Writers

ATLANTA--(BUSINESS WIRE)--Dec. 9, 2003

Ross Systems, (NASDAQ: ROSS), a leading global provider of enterprise software solutions for manufacturers, today announced that Dyax, a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products, is using iRenaissance ERP to support its enterprise operations. Dyax chose Ross Systems' iRenaissance to simplify the integration and consolidation of its global financial operations, improve purchasing and monitor project costs for trial compounds and discovery programs.

Dyax was seeking a solution that could streamline the project accounting for clinical trials and discovery programs, manage purchasing functions and consolidate global financials. The iRenaissance system will help Dyax establish procedures, controls and security to support regulatory requirements of industry agencies such as the U.S. Food and Drug Administration and Medicines Control Agency. Dyax chose Ross because of its ability to meet their operational requirements today, and Ross' deep experience in pharmaceutical manufacturing, which has helped companies meet cGxP and 21 CFR Part 11 regulatory requirements that control the authenticity of electronic documents.

Emerging life sciences companies such as Dyax will benefit from iRenaissance's ability to expand the system to support in-house or outsourced manufacturing for material control, formulation management, planning and traceability. In addition, Dyax will benefit from access to real-time data and improved communication between operations and research.

"We examined numerous options to address the current needs of our company," said Steve Galliker, executive vice president and CFO of Dyax. "What I found most compelling about Ross was its experience and strong biopharmaceutical customer base and, in particular, its ability to support our clinical trial supply chain requirements as we grow. Ross' scalable infrastructure made it affordable to deploy today in a very short time frame and support us long into the future."

As the cost of bringing drugs to market continues to rise, scalable ERP solutions are essential to maintaining lean operations and ensuring that a life science company's resources are devoted to drug discovery and development. By using tailored and sophisticated tools to accurately track the expenses associated with clinical trials, early stage organizations can reduce the cost and waste associated with poor financial controls and visibility, decrease the business risk through better planning and faster clinical trial material fulfillment, and assume the responsibility to deliver cGxP and Part 11 compliant solutions to their customers.

"By providing complete solutions that address these requirements and maintaining a tight focus on the specific needs of the life science industry, we will reduce the costs of clinical trial and commercial operations for our customers," said J. Patrick Tinley, chairman and CEO of Ross Systems. "Based on our experience and understanding of pharmaceutical companies we have designed our products to address multiple business needs at various stages of the drug manufacturing process, providing low total cost of ownership and a path for growth."

About Dyax

Dyax Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products. The company uses its patented phage display technology to rapidly identify a broad range of protein, peptide, and antibody compounds that bind with high affinity and high specificity to targets of interest, with the objective of selecting those compounds with the greatest potential for advancement into clinical development. Dyax currently has two recombinant proteins in phase I and II clinical trials. DX-88 is being studied in two indications (hereditary angioedema and cardiopulmonary bypass), while DX-890 is being studied for cystic fibrosis. Dyax leverages its technology broadly through licenses and collaborations in therapeutics and in non-core areas of affinity separations, diagnostics and imaging, and research reagents. Through its subsidiary, Biotage, Inc., Dyax develops, manufactures and sells chromatography separations systems and products worldwide for drug discovery and purification.

About Ross Systems

Ross Systems, Inc. (NASDAQ: ROSS) delivers innovative software solutions that help manufacturers worldwide fulfill their business growth objectives through increased operational efficiencies, improved profitability, strengthened customer relationships and streamlined regulatory compliance. Focused on the food and beverage, life sciences, chemicals, metals and natural products industries and implemented by more than 1,000 customer companies worldwide, the company's family of Internet-architected solutions is a comprehensive, modular suite that spans the enterprise, from manufacturing, financials and supply chain management to customer relationship management, performance management and regulatory compliance.

Statements in this announcement, which express that the Company "believes", "anticipates", "expects", "plans to..." or "should begin to..." as well as other statements, which are not historical fact, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially as a result of risks and uncertainties, including quarterly fluctuation of software product license revenue, weakening of customer demand for enterprise systems, the Company's maintenance of a minimal backlog, the uncertainty of demand for new product offerings and other risks and uncertainties described in reports filed by the Company with the SEC, including the Annual Report on Form 10-K filed for the year ended June 30, 2003 and the Quarterly Report on Form 10-Q for the quarter ended September 30, 2003. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this announcement. We do not undertake any obligation to publicly update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as required by law.